Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Zejula delayed disease progression in people with advanced ovarian cancer who had a complete or partial response to platinum chemotherapy.
The three studies tested Zejula, Lynparza and veliparib in women with newly diagnosed advanced ovarian cancer.
The indication is for people with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with prior chemotherapy regimens.
Gaby Kressly, now in her early 80s, was diagnosed with ovarian cancer in 2016.
Talazoparib may offer an additional option for women with BRCA gene mutations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.